Kodiak Sciences Past Earnings Performance
Past criteria checks 0/6
Kodiak Sciences's earnings have been declining at an average annual rate of -21.4%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
-21.4%
Earnings growth rate
-18.2%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -103.4% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Dec 13
Kodiak: Tarcocimab Faces High Barriers To Entry Despite Resurrection (Rating Upgrade)
Nov 15We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Aug 02We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Apr 17We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Dec 29We're Keeping An Eye On Kodiak Sciences' (NASDAQ:KOD) Cash Burn Rate
Sep 09Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Deliver On Growth Plans?
May 26We Think Kodiak Sciences (NASDAQ:KOD) Needs To Drive Business Growth Carefully
Jan 04Here's Why We're Watching Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Sep 25GreenWood Investors - Kodiak Sciences: The Busted Biotech World
Aug 25Kodiak Sciences FQ1 2022 Earnings Preview
Aug 07Is Kodiak Sciences (NASDAQ:KOD) In A Good Position To Invest In Growth?
May 18Kodiak Sciences: Potential For Comeback After Trial Setback
May 17Kodiak Sciences: KSI-301 Disappoints
Feb 25Highlighting Kodiak Sciences: A Great Buy Here Ahead Of Phase 3 Wet AMD Data For KSI-301 This Quarter
Feb 15We're Hopeful That Kodiak Sciences (NASDAQ:KOD) Will Use Its Cash Wisely
Jan 24Here's Why We're Not Too Worried About Kodiak Sciences' (NASDAQ:KOD) Cash Burn Situation
Oct 11Kodiak Sciences: Our Current Take On This Mid-Cap Biotech Company
Jul 19Kodiak Sciences EPS in-line
May 10Kodiak Sciences hits the capital raise button; shares dip after hours
Nov 16Kodiak Sciences EPS misses by $0.12
Nov 09Revenue & Expenses Breakdown
How Kodiak Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -192 | 63 | 141 |
| 30 Jun 24 | 0 | -198 | 67 | 145 |
| 31 Mar 24 | 0 | -233 | 69 | 180 |
| 31 Dec 23 | 0 | -260 | 71 | 206 |
| 30 Sep 23 | 0 | -271 | 72 | 216 |
| 30 Jun 23 | 0 | -298 | 72 | 241 |
| 31 Mar 23 | 0 | -309 | 72 | 248 |
| 31 Dec 22 | 0 | -334 | 74 | 268 |
| 30 Sep 22 | 0 | -357 | 73 | 287 |
| 30 Jun 22 | 0 | -347 | 67 | 282 |
| 31 Mar 22 | 0 | -312 | 59 | 253 |
| 31 Dec 21 | 0 | -267 | 50 | 217 |
| 30 Sep 21 | 0 | -220 | 42 | 179 |
| 30 Jun 21 | 0 | -189 | 38 | 152 |
| 31 Mar 21 | 0 | -159 | 33 | 128 |
| 31 Dec 20 | 0 | -133 | 29 | 107 |
| 30 Sep 20 | 0 | -102 | 22 | 83 |
| 30 Jun 20 | 0 | -78 | 18 | 64 |
| 31 Mar 20 | 0 | -64 | 15 | 52 |
| 31 Dec 19 | 0 | -47 | 12 | 38 |
| 30 Sep 19 | 0 | -46 | 11 | 32 |
| 30 Jun 19 | 0 | -44 | 10 | 26 |
| 31 Mar 19 | 0 | -41 | 8 | 21 |
| 31 Dec 18 | 0 | -41 | 8 | 19 |
| 30 Sep 18 | 0 | -38 | 6 | 21 |
| 30 Jun 18 | 0 | -32 | 5 | 19 |
| 31 Mar 18 | 0 | -31 | 5 | 21 |
| 31 Dec 17 | 0 | -28 | 3 | 22 |
Quality Earnings: KOD is currently unprofitable.
Growing Profit Margin: KOD is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KOD is unprofitable, and losses have increased over the past 5 years at a rate of 21.4% per year.
Accelerating Growth: Unable to compare KOD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KOD is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (20%).
Return on Equity
High ROE: KOD has a negative Return on Equity (-103.37%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/03 00:32 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Kodiak Sciences Inc. is covered by 17 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Anita Dushyanth | Berenberg |
| Matthew Luchini | BMO Capital Markets Equity Research |